Condition: Hypercholesterolemia · Sponsor: Kowa Company, Ltd.
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
This description comes directly from the study's public registry record.
Kaho Ikegami · 81-3-3279-7454 · ctrdinfo@kowa.co.jp
Always discuss trial participation with your own doctor first.
| NTT Medical Center Sapporo | Hokkaido, Japan | Recruiting |
| Ami Higashi Clinic | Ibaraki, Japan | Recruiting |
| Olive Takamatsu Medical Clinic | Kagawa, Japan | Recruiting |
| Medical Corporation Shintokai Yokohama Minoru Clinic | Kanagawa, Japan | Recruiting |
| Medical Corporation Heishinkai OCROM Clinic | Osaka, Japan | Recruiting |
| Hirose Clinic | Saitama, Japan | Recruiting |
| Medical Corporation Yukeikai Asano Internal Medicine Clinic | Saitama, Japan | Recruiting |
| Medical Corporation Asbo Tokyo Asbo Clinic | Tokyo, Japan | Recruiting |
| Medical Corporation Heishinkai ToCROM Clinic | Tokyo, Japan | Recruiting |
| Shimokitazawa Tomo Clinic | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07634484